Drug recall · November 23, 2022
PF-Neostigmine Methylsulfate Injection recall
Why: CGMP Deviations: Potential for cross contamination due to product carry over.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
PF-Neostigmine Methylsulfate Injection, USP 3 mg/3 mL (1 mg/mL) vial, Rx Only, Nephron 503B Outsourcing Facility 4500 12th Street Extension West Columbia, SC 29172, NDC 69374-932-33, UPC 3 69374-93233 2.
- Lots / codes
Lots: NE1062A, NE1062B Exp. 12/02/2022; NE1065A, NE1065B Exp. 12/13/2022; NE2011A, NE2011B Exp. 03/15/2022.
- Quantity
- 56,220 vials
- Company
- Nephron Sterile Compounding Center LLC, West Columbia, SC
- Distribution
- Nationwide in the USA
- Initiated
- November 10, 2022 · Voluntary: Firm initiated
- Classified
- November 17, 2022
- Reported
- November 23, 2022
- Ended
- September 24, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Neostigmine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.